TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07556471: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo

Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 180 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,256,000

Rescue Site Savings

+$5,443,800

Unlock Full NCT07556471 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07556471 Rescue Dossier →